Multimodality Prognostic Score (MMPS) of Opitz et al for a Patient with a Malignant Pleural Mesothelioma

Description

Opitz et al reported the Multimodality Prognostic Score (MMPS) for a patient with malignant mesothelioma. This can help to identify a patient who may benefit from more aggressive management including surgery. The authors are from University Hospital Zurich and Medical University Vienna.

Patient selection: pleural malignant mesothelioma, T1 to T3, pN0 to pN2, M0

Parameters:

(1) pre-chemotherapy volume in mL

(2) serum CRP before chemotherapy in mg/L

(3) histology in pre-chemotherapy biopsy

(4) progressive disease after therapy by the modified RECIST criteria

Parameter	Finding	Points
volume	<= 500 mL	0
	> 500 mL	1
serum CRP	<= 30 mg/L	0
	> 30 mg/L	1
histology	epithelioid	0
	nonepithelioid	1
progressive disease	no	0
	yes	1

total score =

= SUM(points for all 4 parameters)

Interpretation:

• minimum score: 0

• maximum score: 4

• The higher the score the worse the outcome.

• A patient with a score > 2 would not benefit from multimodal therapy.

Score	Median Survival
0	34 months
1	17 months
2	12 months
3	4 months
4	4 months

To read more or access our algorithms and calculators, please log in or register.

Multimodality Prognostic Score (MMPS) of Opitz et al for a Patient with a Malignant Pleural Mesothelioma

Description

Specialty